Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2, Open-Label Clinical Study to Evaluate the Safety and Efficacy of Intrathecal TSHA-101 Gene Therapy for Treatment of Infantile Onset GM2 Gangliosidosis

Trial Profile

Phase 1/2, Open-Label Clinical Study to Evaluate the Safety and Efficacy of Intrathecal TSHA-101 Gene Therapy for Treatment of Infantile Onset GM2 Gangliosidosis

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 21 Feb 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TSHA 101 (Primary)
  • Indications GM2 gangliosidoses
  • Focus Adverse reactions; First in man

Most Recent Events

  • 15 Feb 2024 According to a Taysha Gene Therapies media release, The Company transferred rights back to Queen's University (Queen's) for TSHA-101 in GM2 gangliosidosis, resulting in Queen's regaining exclusive IP to the program.
  • 08 May 2023 Planned primary completion date changed from 12 Mar 2023 to 12 Mar 2027.
  • 12 Sep 2022 Status changed from suspended to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top